Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study

PURPOSE: A three-drug combination of cyclophosphamide, bortezomib, and dexamethasone (CVD) shows significant efficacy and manageable toxicity as induction therapy in patients with multiple myeloma. MATERIALS AND METHODS: In this phase II study, we enrolled 45 patients who achieved a very good partia...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Jongheon, Kim, Kihyun, Jung, Sung-Hoon, Yoon, Sung-Soo, Lee, Jae Hoon, Kim, Jin Seok, Shin, Ho-Jin, Bang, Soo-Mee, Sohn, Sang Kyun, Suh, Cheolwon, Yoon, Dok Hyun, Kong, Sun-Young, Min, Chang-Ki, Eom, Hyeon-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101807/
https://www.ncbi.nlm.nih.gov/pubmed/36397235
http://dx.doi.org/10.4143/crt.2022.952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101807/
https://www.ncbi.nlm.nih.gov/pubmed/36397235
http://dx.doi.org/10.4143/crt.2022.952

Ejemplares similares